Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 22;23(1):146.
doi: 10.1186/s13075-021-02524-9.

Opioid users show worse baseline knee osteoarthritis and faster progression of degenerative changes: a retrospective case-control study based on data from the Osteoarthritis Initiative (OAI)

Affiliations

Opioid users show worse baseline knee osteoarthritis and faster progression of degenerative changes: a retrospective case-control study based on data from the Osteoarthritis Initiative (OAI)

Jannis Bodden et al. Arthritis Res Ther. .

Abstract

Background: Opioids are frequently prescribed for pain control in knee osteoarthritis patients, despite recommendations by current guidelines. Previous studies have investigated the chondrotoxicity of different opioid subtypes. However, the impact opioids may have on progression of osteoarthritis in vivo remains unknown. The aim of this study was thus to describe the associations between opioid use and knee structural changes and clinical outcomes, over 4 years.

Methods: Participants with baseline opioid use (n=181) and who continued use for ≥1 year between baseline and 4-year follow-up (n=79) were included from the Osteoarthritis Initiative cohort and frequency matched with non-users (controls) (1:2). Whole-Organ Magnetic Resonance Imaging Scores (WORMS) were obtained, including a total summation score (WORMS total, range 0-96) and subscores for cartilage (0-36), menisci (0-24), and bone marrow abnormalities and subchondral cyst-like lesions (0-18, respectively). Knee Injury Osteoarthritis Outcomes score (KOOS) symptoms, quality of life (QOL), and pain were also obtained at baseline and follow-up (range 0-100; lower scores indicate worse outcomes). Using linear regression models, associations between baseline and longitudinal findings were investigated. As pain may modify observations, a sensitivity analysis was performed for longitudinal findings. All analyses were adjusted for sex, BMI, age, race, and Kellgren-Lawrence grade.

Results: Opioid users had greater structural degeneration at baseline (WORMS total: Coef. [95% CI], P; 7.1 [5.5, 8.8], <0.001) and a greater increase over 4 years (4.7 [2.9, 6.5], <0.001), compared to controls. Cartilage and meniscus scores increased greater in opioid users, compared to controls (P≤0.001), and findings withstood the adjustment for baseline pain (P≤0.002). All baseline KOOS scores were lower in opioid users compared to controls (P<0.001). QOL loss was greater, when adjusted for baseline KOOS pain (QOL -6.9 [-11.6, -2.1], 0.005).

Conclusions: Opioid users had worse baseline knee structural degeneration and faster progression. Opioid use was also associated with worse symptoms, pain, and QOL. Furthermore, QOL loss was greater in opioid users compared to controls, when adjusted for baseline KOOS pain, indicating that opioids may not be suited to prevent subjective disease progression in KOA patients.

Keywords: Knee; Magnetic resonance imaging; Opioids; Osteoarthritis; Osteoarthritis Initiative; Pain.

PubMed Disclaimer

Conflict of interest statement

J.B., S.S., G.B.J., and N.E.L declare that they have no competing interests. J.A.L. reported paid consulting activity for the Boston Imaging Core Lab, not related to this work. M.C.N. and C.E.M. reported funding by NIH. T.M.L. reported funding by NIH/NIAMS.

Figures

Fig. 1
Fig. 1
Flow chart depicting inclusion and exclusion criteria for opioid user cohorts. Cross-sectional opioid use was defined by the MIFUSE variable (MIFUSE = 1). Longitudinal opioid use was defined as opioid use at baseline and 4-year follow-up (MIFUSE = 1, respectively) and opioid use duration of at least 1 year at follow-up (MIFDUR ≥ 3)
Fig. 2
Fig. 2
Severe progression of right knee degenerative changes over 4 years in an opioid user. Images were reviewed on picture archiving and communication system (PACS) workstations. Coronal views from intermediate-weighted sequences. a Baseline exam. Beginning extrusion and intra-substance lesion of the lateral meniscal body (arrowhead) and cartilage signal abnormality at the lateral tibial plateau (arrow). b Deterioration and progressive extrusion of the lateral meniscal body. Full-thickness cartilage loss at the medial femoral condyle (> 1 cm) and medial tibial plateau (> 1 cm) (arrow). Of note, new partial thickness cartilage loss at the medial femoral condyle and new, large subchondral cyst at the medial tibial plateau (arrowhead)
Fig. 3
Fig. 3
Right knee degenerative changes over 4 years in a control subject. Images were reviewed on picture archiving and communication system (PACS) workstations. Coronal views from intermediate-weighted sequences. a Baseline exam. Nondisplaced, horizontal tear in the white zone of the lateral meniscal body (arrow). Complex tear of the medial meniscal body with displaced flap (arrowhead). b Four-year follow-up exam. While the horizontal tear of the lateral meniscal body is more distinct, the tear type is stable. Stable complex tear of the medial meniscal body with flap. Of note, absence of cartilage lesions at baseline and follow-up

References

    1. Felson DT, Naimark A, Anderson J, Kazis L, Castelli W, Meenan RF. The prevalence of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. Arthritis & Rheumatism. 1987;30(8):914–918. doi: 10.1002/art.1780300811. - DOI - PubMed
    1. Wallace IJ, Worthington S, Felson DT, Jurmain RD, Wren KT, Maijanen H, Woods RJ, Lieberman DE. Knee osteoarthritis has doubled in prevalence since the mid-20th century. Proc Natl Acad Sci U S A. 2017;114(35):9332–9336. doi: 10.1073/pnas.1703856114. - DOI - PMC - PubMed
    1. Krebs EE, Gravely A, Nugent S, Jensen AC, DeRonne B, Goldsmith ES, Kroenke K, Bair MJ, Noorbaloochi S. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE randomized clinical trial. Jama. 2018;319(9):872–882. doi: 10.1001/jama.2018.0899. - DOI - PMC - PubMed
    1. DeMik DE, Bedard NA, Dowdle SB, Burnett RA, McHugh MA, Callaghan JJ. Are we still prescribing opioids for osteoarthritis? J Arthroplasty. 2017;32(12):3578–3582.e3571. doi: 10.1016/j.arth.2017.07.030. - DOI - PubMed
    1. Thorlund JB, Turkiewicz A, Prieto-Alhambra D, Englund M. Opioid use in knee or hip osteoarthritis: a region-wide population-based cohort study. Osteoarthritis Cartilage. 2019;27(6):871–877. doi: 10.1016/j.joca.2019.01.005. - DOI - PubMed

Publication types

Substances